Table 5.

Hepatotoxicity of highly active anti-retroviral therapy drugs and guidelines for their use in patients with liver disease

Group	Drug	Dose adjustment
NRTI	Didanosine	Use cautiously
NNRTI	Delavirdine, Efavirenz, Nevirapine	Caution with hepatic impairment
PIs	Lopinavir, Nelfinavir, Ritonavir, Saquinavir	Caution with hepatic impairment
	Atazanavir	Reduce 25% of dose in patients with CTP stage B and C
	Indinavir	Reduce dose by 25% in CTP stage B and C
	Tipranavir	Avoid in patients with CTP stage B or C
	Fosamprenavir	Avoid in patients with CTP stage C
	Darunavir	Avoid in patients with CTP stage C